Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Follistim AQ Clears FDA; Formulation Has Dosing Advantage, Firm Says

This article was originally published in The Pink Sheet Daily

Executive Summary

The ready-to-inject infertility treatment delivers 18% more follitropin beta than a conventional syringe, Organon says. The company also hopes to launch its implantable contraceptive Implanon this year.

You may also be interested in...



Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment

Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.

Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment

Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.

Organon Building New Quality Affairs Group; New Jersey Plant To Close

The West Orange, N.J. facility’s closure will affect 220 employees and result in the discontinuation of three products. Organon hopes to offer 45-50 positions in quality affairs to affected staff.

Topics

UsernamePublicRestriction

Register

PS012935

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel